KR102237364B1 - 올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법 - Google Patents

올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법 Download PDF

Info

Publication number
KR102237364B1
KR102237364B1 KR1020157009160A KR20157009160A KR102237364B1 KR 102237364 B1 KR102237364 B1 KR 102237364B1 KR 1020157009160 A KR1020157009160 A KR 1020157009160A KR 20157009160 A KR20157009160 A KR 20157009160A KR 102237364 B1 KR102237364 B1 KR 102237364B1
Authority
KR
South Korea
Prior art keywords
disease
compound
disorder
compounds
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157009160A
Other languages
English (en)
Korean (ko)
Other versions
KR20150053982A (ko
Inventor
신 지앙
크리스토퍼 에프. 벤더
멜리언 비스닉
Original Assignee
리아타 파마슈티컬즈, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리아타 파마슈티컬즈, 아이엔씨. filed Critical 리아타 파마슈티컬즈, 아이엔씨.
Publication of KR20150053982A publication Critical patent/KR20150053982A/ko
Application granted granted Critical
Publication of KR102237364B1 publication Critical patent/KR102237364B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Lubricants (AREA)
  • Steroid Compounds (AREA)
  • Epidemiology (AREA)
KR1020157009160A 2012-09-10 2013-09-10 올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법 Active KR102237364B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699199P 2012-09-10 2012-09-10
US61/699,199 2012-09-10
PCT/US2013/059015 WO2014040056A1 (en) 2012-09-10 2013-09-10 C17-heteroaryl derivatives of oleanolic acid and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20150053982A KR20150053982A (ko) 2015-05-19
KR102237364B1 true KR102237364B1 (ko) 2021-04-06

Family

ID=49253401

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157009160A Active KR102237364B1 (ko) 2012-09-10 2013-09-10 올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법

Country Status (28)

Country Link
US (1) US20140088163A1 (enExample)
EP (1) EP2892911B1 (enExample)
JP (1) JP6272870B2 (enExample)
KR (1) KR102237364B1 (enExample)
CN (1) CN104768965B (enExample)
AU (1) AU2013312102B2 (enExample)
BR (1) BR112015005200B1 (enExample)
CA (1) CA2882417C (enExample)
CY (1) CY1119762T1 (enExample)
DK (1) DK2892911T3 (enExample)
EA (1) EA029069B1 (enExample)
ES (1) ES2644615T3 (enExample)
HR (1) HRP20171565T1 (enExample)
HU (1) HUE036797T2 (enExample)
IL (1) IL237638B (enExample)
IN (1) IN2015DN01547A (enExample)
LT (1) LT2892911T (enExample)
ME (1) ME02911B (enExample)
MX (1) MX366954B (enExample)
NZ (1) NZ705213A (enExample)
PL (1) PL2892911T3 (enExample)
PT (1) PT2892911T (enExample)
RS (1) RS56563B1 (enExample)
SG (1) SG11201501800UA (enExample)
SI (1) SI2892911T1 (enExample)
SM (1) SMT201700501T1 (enExample)
WO (1) WO2014040056A1 (enExample)
ZA (1) ZA201501203B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI492745B (zh) 2008-01-11 2015-07-21 Reata Pharmaceuticals Inc 合成的三萜系化合物及其使用於治療疾病之方法
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
MX2010011435A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
NZ612788A (en) 2010-12-17 2015-10-30 Reata Pharmaceuticals Inc Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
SI3444261T1 (sl) 2012-04-27 2021-04-30 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamidni derivat bardoksolon metila, njegovi farmacevtski sestavki in polimorfi za uporabo pri zdravljenju določenih stanj
WO2013188818A1 (en) 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY35534A (es) 2013-04-24 2014-10-31 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
NZ734292A (en) 2015-02-12 2022-09-30 Reata Pharmaceuticals Inc Imidazolyl tricyclic enones as antioxidant inflammation modulators
MX386256B (es) 2015-09-23 2025-03-18 Reata Pharmaceuticals Inc Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
WO2019055119A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.
CN106632574B (zh) * 2016-12-07 2018-05-29 广东天键生物科技有限公司 一种化合物、其制备方法及用途
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
MX2020002884A (es) 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
IL279348B2 (en) 2018-06-15 2026-01-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
MX2021003643A (es) * 2018-09-28 2021-08-19 Sichuan Haisco Pharmaceutical Co Ltd Derivados de terpenoides y usos de los mismos.
WO2021016191A1 (en) * 2019-07-19 2021-01-28 Reata Pharmaceuticals, Inc. C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection
RU2020130238A (ru) 2020-03-31 2022-03-14 Феникс Байотекнолоджи, Инк. Способ и композиции для лечения коронавирусной инфекции
JP7214696B2 (ja) * 2020-10-01 2023-01-30 一般財団法人 化学物質評価研究機構 新規ｉｎ ｖｉｔｒｏ皮膚感作性試験法
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
US20240140986A1 (en) 2021-01-18 2024-05-02 Reata Pharmaceuticals, Inc. Synthetic ursolic acid derivatives and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518192A (ja) * 2008-04-18 2011-06-23 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７同族体化オレアノール酸誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6974801B2 (en) * 2002-05-13 2005-12-13 The Trustees Of Dartmounth College Inhibitors and methods of use thereof
TWI492745B (zh) 2008-01-11 2015-07-21 Reata Pharmaceuticals Inc 合成的三萜系化合物及其使用於治療疾病之方法
EA022588B1 (ru) * 2008-04-18 2016-01-29 Ритэ Фамэсутикл, Инк. Антиоксидантные модуляторы воспаления: производные олеанолевой кислоты с насыщением в с-кольце
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
EP2683731B1 (en) * 2011-03-11 2019-04-24 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011518192A (ja) * 2008-04-18 2011-06-23 リアタ ファーマシューティカルズ インコーポレイテッド 抗酸化炎症モジュレーター：ｃ−１７同族体化オレアノール酸誘導体

Also Published As

Publication number Publication date
SI2892911T1 (sl) 2017-12-29
EA029069B1 (ru) 2018-02-28
US20140088163A1 (en) 2014-03-27
CN104768965B (zh) 2018-05-11
HUE036797T2 (hu) 2018-07-30
CY1119762T1 (el) 2018-06-27
IL237638B (en) 2020-04-30
ES2644615T3 (es) 2017-11-29
CN104768965A (zh) 2015-07-08
KR20150053982A (ko) 2015-05-19
EP2892911A1 (en) 2015-07-15
HK1211295A1 (en) 2016-05-20
RS56563B1 (sr) 2018-02-28
LT2892911T (lt) 2017-11-10
PL2892911T3 (pl) 2018-03-30
IL237638A0 (en) 2015-04-30
MX2015003078A (es) 2015-07-14
ZA201501203B (en) 2021-08-25
DK2892911T3 (en) 2017-10-23
HRP20171565T1 (hr) 2017-12-15
SMT201700501T1 (it) 2017-11-15
JP2015529227A (ja) 2015-10-05
NZ705213A (en) 2018-07-27
AU2013312102B2 (en) 2018-03-08
JP6272870B2 (ja) 2018-01-31
PT2892911T (pt) 2017-11-02
BR112015005200B1 (pt) 2022-07-05
SG11201501800UA (en) 2015-04-29
EP2892911B1 (en) 2017-08-30
CA2882417A1 (en) 2014-03-13
BR112015005200A2 (enExample) 2017-08-15
MX366954B (es) 2019-07-31
IN2015DN01547A (enExample) 2015-07-03
WO2014040056A1 (en) 2014-03-13
CA2882417C (en) 2021-04-20
EA201590539A1 (ru) 2015-08-31
ME02911B (me) 2018-10-20
AU2013312102A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
KR102237364B1 (ko) 올레아놀산의 ｃ１７―헤테로아릴 유도체 및 그의 사용 방법
KR102237359B1 (ko) 올레아놀산의 ｃ１７―알칸디일 및 알켄디일 유도체 및 그의 사용 방법
US11406648B2 (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9290536B2 (en) C4 monomethyl triterpenoid derivatives and methods of use thereof
US9556222B2 (en) A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
HK1211295B (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150409

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180906

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191205

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20200722

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210107

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210401

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210401

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240319

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250324

Start annual number: 5

End annual number: 5